Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filipa Lynce

Showing results (21-30 of 96) with videos related to

Pageof 10
Sort By:
Contemporary Clinical Trials Communications|April 7, 2023
A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aromatase inhibitor and a CDK4/6 inhibitorTina Roy, Elizabeth Barrows, Candace Mainor, et al.
NPJ Breast Cancer|July 21, 2025
Real-world effectiveness of palbociclib plus an aromatase inhibitor in HR+/HER2- MBC patients living in disadvantaged neighborhoodsFilipa Lynce, Xianchen Liu, Benjamin Li, et al.
Journal of Cardiovascular Translational Research|May 28, 2020
Trends in the Use of Cardiac Imaging for Women with Newly Diagnosed Breast CancerAna Barac, Claudine Isaacs, Nawar M Shara, et al.
Journal for Immunotherapy of Cancer|April 24, 2025
Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunotherapy, chemotherapy, or chemoimmunotherapyNicole J Toney, Megan T Lynch, Filipa Lynce, et al.
Cells|April 13, 2023
Copy Number Variation in Inflammatory Breast CancerAditi Hazra, Andrea O'Hara, Kornelia Polyak, et al.
Breast Cancer Research and Treatment|November 10, 2017
Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trialsFilipa Lynce, Matthew J Blackburn, Ling Cai, et al.
Breast Cancer Research and Treatment|August 8, 2015
Deleterious BRCA1/2 mutations in an urban population of Black womenFilipa Lynce, Karen Lisa Smith, Julie Stein, et al.
The Oncologist|March 19, 2017
SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular FunctionFilipa Lynce, Ana Barac, Ming T Tan, et al.
Oncology and Therapy|April 15, 2025
Oncotype DX Recurrence Score and Germline BRCA Variants in Patients with HR-Positive/HER2-Negative Early Breast Cancer: A Retrospective Observational StudyStefania Morganti, Rabia A Khan, Luis C Berrocal-Almanza, et al.
Cancer Control : Journal of the Moffitt Cancer Center|November 15, 2016
Genomic Disparities in Breast Cancer Among LatinasFilipa Lynce, Kristi D Graves, Lina Jandorf, et al.
Pageof 10

Showing results (21-30 of 96) with videos related to

Sort By:
Pageof 10
Contemporary Clinical Trials Communications|April 7, 2023
A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aromatase inhibitor and a CDK4/6 inhibitorTina Roy, Elizabeth Barrows, Candace Mainor, et al.
NPJ Breast Cancer|July 21, 2025
Real-world effectiveness of palbociclib plus an aromatase inhibitor in HR+/HER2- MBC patients living in disadvantaged neighborhoodsFilipa Lynce, Xianchen Liu, Benjamin Li, et al.
Journal of Cardiovascular Translational Research|May 28, 2020
Trends in the Use of Cardiac Imaging for Women with Newly Diagnosed Breast CancerAna Barac, Claudine Isaacs, Nawar M Shara, et al.
Journal for Immunotherapy of Cancer|April 24, 2025
Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunotherapy, chemotherapy, or chemoimmunotherapyNicole J Toney, Megan T Lynch, Filipa Lynce, et al.
Cells|April 13, 2023
Copy Number Variation in Inflammatory Breast CancerAditi Hazra, Andrea O'Hara, Kornelia Polyak, et al.
Breast Cancer Research and Treatment|November 10, 2017
Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trialsFilipa Lynce, Matthew J Blackburn, Ling Cai, et al.
Breast Cancer Research and Treatment|August 8, 2015
Deleterious BRCA1/2 mutations in an urban population of Black womenFilipa Lynce, Karen Lisa Smith, Julie Stein, et al.
The Oncologist|March 19, 2017
SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular FunctionFilipa Lynce, Ana Barac, Ming T Tan, et al.
Oncology and Therapy|April 15, 2025
Oncotype DX Recurrence Score and Germline BRCA Variants in Patients with HR-Positive/HER2-Negative Early Breast Cancer: A Retrospective Observational StudyStefania Morganti, Rabia A Khan, Luis C Berrocal-Almanza, et al.
Cancer Control : Journal of the Moffitt Cancer Center|November 15, 2016
Genomic Disparities in Breast Cancer Among LatinasFilipa Lynce, Kristi D Graves, Lina Jandorf, et al.
Pageof 10